Amylyx updates corporate presentation: Phase 3 LUCIDITY enrollment complete, Phase 2 PREVENT analysis added

Amylyx Pharmaceuticals, Inc.

Completed enrollment in Phase 3 LUCIDITY trial.
Added exploratory analysis of Phase 2 PREVENT study from ENDO 2025.
Completed enrollment for Cohort 2 of Phase 1 LUMINA trial.

item 7.01 item 9.01

Amylyx Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-120691

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.